Sotatercept in patients with osteolytic lesions of multiple myeloma

British Journal of Haematology

Volumn 165, Issue 6, 2014, Pages 814-823

  Abdulkadyrov, Kudrat M ^a   Salogub, Galina N ^b   Khuazheva, Nuriet K ^c   Sherman, Matthew L ^d   Laadem, Abderrahmane ^e   Barger, Rachel ^d   Knight, Robert ^e   Srinivasan, Shankar ^e   Terpos, Evangelos ^f  

^a Research Institute of Haematology and Blood Transfusion   (Russian Federation)

^b PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^c Moscow Municipal Clinical Hospital No 52   (Russian Federation)

^d Acceleron Pharma Inc   (United States)

^e CELGENE CORPORATION   (United States)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Anaemia; Bone disease; Haematopoiesis; Multiple myeloma; Sotatercept

Indexed keywords

HEMOGLOBIN; MELPHALAN; PLACEBO; PREDNISOLONE; SOTATERCEPT; THALIDOMIDE;

ARTICLE; BONE ATROPHY; BONE DENSITY; BONE METABOLISM; BONE PAIN; COMPRESSION FRACTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; GRANULOCYTOPENIA; HEART ATRIUM FIBRILLATION; HEMATOPOIESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OSTEOLYSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIB FRACTURE; TREATMENT DURATION;

ANAEMIA; BONE DISEASE; HAEMATOPOIESIS; MULTIPLE MYELOMA; SOTATERCEPT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BONE DENSITY; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; OSTEOGENESIS; OSTEOLYSIS; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 84901692001     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12835     Document Type: Article

References (39)

1. Abildgaard, N., Brixen, K., Eriksen, E.F., Kristensen, J.E., Nielsen, J.L. & Heickendorff, L. (2004) Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica, 89, 567-577.
2. Berenson, J.R., Lichtenstein, A., Porter, L., Dimopoulos, M.A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., Blacklock, H., Bell, R., Simeone, J.F., Reitsma, D.J., Heffernan, M., Seaman, J. & Knight, R.D. (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. Journal of Clinical Oncology, 16, 593-602.
3. Bladé, J., Samson, D., Reece, D., Apperley, J., Björkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 1115-1123.
4. Chang, J.T., Green, L. & Beitz, J. (2003) Renal failure with the use of zoledronic acid. New England Journal of Medicine, 349, 1676-1679.
5. Chantry, A., Heath, D., Coulton, L., Gallagher, O., Evans, H., Seehra, J., Vanderkerken, K. & Croucher, P.I. (2007) A soluble activin type II receptor prevents myeloma bone disease [Abstract]. Haematologica, 92 (6 Suppl. 2), 133.
6. Dimopoulos, M.A., Kastritis, E., Anagnostopoulos, A., Melakopoulos, I., Gika, D., Moulopoulos, L.A., Bamia, C., Terpos, E., Tsionos, K. & Bamias, A. (2006) Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica, 91, 968-971.
7. Fajardo, R.J., Manoharan, R.K., Pearsall, R.S., Davies, M.V., Marvell, T., Monnell, T.E., Ucran, J.A., Pearsall, A.E., Khanzode, D., Kumar, R., Underwood, K.W., Roberts, B., Seehra, J. & Bouxsein, M.L. (2010) Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis). Bone, 46, 64-71.
8. Groopman, J.E. & Itri, L.M. (1999) Chemotherapy-induced anemia in adults: incidence and treatment. Journal of the National Cancer Institute, 91, 1616-1634.
9. Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.D., Schilcher, B., Mose, S., Beer, K.T., Burger, U., Dougherty, C. & Frommhold, H. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. The Lancet, 362, 1255-1260.
10. Hussein, M.A. (2007) Multiple myeloma: most common end-organ damage and management. Journal of the National Comprehensive Cancer Network, 5, 170-178.
11. Kyle, R.A. (1975) Multiple myeloma: review of 869 cases. Mayo Clinical Proceedings, 50, 29-40.
12. Kyle, R.A., Gertz, M.A., Witzig, T.E., Lust, J.A., Lacy, M.Q., Dispenzieri, A., Fonseca, R., Rajkumar, S.V., Offord, J.R., Larson, D.R., Plevak, M.E., Therneau, T.M. & Greipp, P.R. (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinical Proceedings, 78, 21-33.
13. Kyle, R.A., Yee, G.C., Somerfield, M.R., Flynn, P.J., Halabi, S., Jagannath, S., Orlowski, R.Z., Roodman, D.G., Twilde, P., Anderson, K. & American Society of Clinical Oncology. (2007) American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. Journal of Clinical Oncology, 25, 2464-2472.
14. Leyland-Jones, B., Semiglazov, V., Pawlicki, M., Pienkowski, T., Tjulandin, S., Manikhas, G., Makhson, A., Roth, A., Dodwell, D., Baselga, J., Biakhov, M., Valuckas, K., Voznyi, E., Liu, X. & Vercammen, E. (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. Journal of Clinical Oncology, 23, 5960-5972.
15. Lotinun, S., Pearsall, R.S., Davies, M.V., Marvell, T.H., Monnell, T.E., Ucran, J., Fajardo, R.J., Kumar, R., Underwood, K.W., Seehra, J., Bouxsein, M.L. & Baron, R. (2010) A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone, 46, 1082-1088.
16. Ludwig, H., Rai, K., Blade, J., Dammacco, F., Degos, L., Itri, L., Kyle, R., Liso, V., Littlewood, T.J., Mandelli, F., Meloni, G., Molica, S., Osterborg, A., Pangalis, G.A., San Miguel, J., Schmitt, B. & Voliotis, D. (2002) Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. The Hematology Journal, 3, 121-130.
17. Minter, A.R., Simpson, H., Weiss, B.M. & Landgren, O. (2011) Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities. Seminars in Hematology, 48, 55-65.
18. Morgan, G.J., Child, J.A., Gregory, W.M., Szubert, A.J., Cocks, K., Bell, S.E., Navarro-Coy, N., Drayson, M.T., Owen, R.G., Feyler, S., Ashcroft, A.J., Ross, F.M., Byrne, J., Roddie, H., Rudin, C., Cook, G., Jackson, G.H., Wu, P., Davies, F.E. & National Cancer Research Institute Haematological Oncology Clinical Studies Group. (2011) Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. The Lancet Oncology, 12, 743-752.
19. Pearsall, R.S., Canalis, E., Cornwall-Brady, M., Underwood, K.W., Haigis, B., Ucran, J., Kumar, R., Pobre, E., Grinberg, A., Werner, E.D., Glatt, V., Stadmeyer, L., Smith, D., Seehra, J. & Bouxsein, M.L. (2008) A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proceedings of the National Academy of Sciences of the United States of America, 105, 7082-7087.
20. Raje, N. & Vallet, S. (2010) Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Current opinion in molecular therapeutics, 5, 586-597.
21. Rodan, G.A. (1997) Bone mass homeostasis and bisphosphonate action. Bone, 20, 1-4.
22. Rosen, L.S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M.A., Coleman, R.E., Reitsma, D.J., Chen, B.L. & Seaman, J.J. (2003a) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter comparative trial. Cancer, 98, 1735-1744.
23. Rosen, L.S., Gordon, D., Tchekmedyian, S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., Reitsma, D. & Seaman, J.J. (2003b) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. Journal of Clinical Oncology, 21, 3150-3157.
24. Ruckle, J., Jacobs, M., Kramer, W., Pearsall, A.E., Kumar, R., Underwood, K.W., Seehra, J., Yang, Y., Condon, C.H. & Sherman, M.L. (2009) Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. Journal of Bone and Mineral Research, 24, 744-752.
25. Saad, F., Gleason, D.M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J.L., Vinholes, J.J., Goas, J.A., Chen, B. & Zoledronic Acid Prostate Cancer Study Group. (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 94, 1458-1468.
26. Sherman, M.L., Borgstein, N.G., Mook, L., Wilson, D., Yang, Y., Chen, N., Kumar, R., Kim, K. & Laadem, A. (2013) Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. The Journal of Clinical Pharmacology, 11, 1121-1130.
27. Shiozaki, M., Sakai, R., Tabuchi, M., Nakamura, T., Sugino, K., Sugino, H. & Eto, Y. (1992) Evidence for the participation of endogenous activin A/erythroid differentiation factor in the regulation of erythropoiesis. Proceedings of the National Academy of Sciences of the United States of America, 89, 1553-1556.
28. Sugatani, T., Alvarez, U.M. & Hruska, K.A. (2003) Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. Journal of Cellular Biochemistry, 90, 59-67.
29. Tai, Y.T., Chang, B.Y., Kong, S.Y., Fulciniti, M., Yang, G., Calle, Y., Hu, Y., Lin, J., Zhao, J.J., Cagnetta, A., Cea, M., Sellitto, M.A., Zhong, M.Y., Wang, Q., Acharya, C., Carrasco, D.R., Buggy, J.J., Elias, L., Treon, S.P., Matsui, W., Richardson, P., Munshi, N.C. & Anderson, K.C. (2012) Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood, 120, 1877-1887.
30. Terpos, E., Kastritis, E., Roussou, M., Heath, D., Christoulas, D., Anagnostopoulos, N., Eleftherakis-Papaiakovou, E., Tsionos, K., Croucher, P. & Dimopoulos, M.A. (2008) The combination of bortezomib, melphalan, dexamethasone, and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia, 22, 2247-2256.
31. Terpos, E., Sezer, O., Croucher, P.I., García-Sanz, R., Boccadoro, M., San Miguel, J., Ashcroft, J., Bladé, J., Cavo, M., Delforge, M., Dimopoulos, M.A., Facon, T., Macro, M., Waage, A., Sonneveld, P. & European Myeloma Network. (2009) The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Annals of Oncology, 20, 1303-1317.
32. Terpos, E., Dimopoulos, M.A., Sezer, O., Roodman, D., Abildgaard, N., Vescio, R., Tosi, P., Garcia-Sanz, R., Davies, F., Chanan-Khan, A., Palumbo, A., Sonneveld, P., Drake, M.T., Harousseau, J.L., Anderson, K.C., Durie, B.G. & International Myeloma Working Group (2010a) The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia, 24, 1700-1712.
33. Terpos, E., Christoulas, D., Kokkoris, P., Anargyrou, K., Gavriatopoulou, M., Migkou, M., Tsionos, K. & Dimopoulos, M.A. (2010b) Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone, and zoledronic acid. Annals of Oncology, 21, 1561-1562.
34. Terpos, E., Berenson, J., Cook, R.J., Lipton, A. & Coleman, R.E. (2010c) Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia, 24, 1043-1049.
35. Terpos, E., Kastritis, E., Christoulas, D., Gkotzamanidou, M., Eleutherakis-Papaiakovou, E., Kanellias, N., Papatheodorou, A. & Dimopoulos, M.A. (2012) Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Annals of Oncology, 23, 2681-2686.
36. Terpos, E., Christoulas, D., Kastritis, E., Katodritou, E., Papatheodorou, A., Pouli, A., Kyrtsonis, M.C., Michalis, E., Papanikolaou, X., Gkotzamanidou, M., Koulieris, E., Gavriatopoulou, M., Zervas, K., Dimopoulos, M.A. & on behalf of the Greek Myeloma Study Group. (2013) The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group. American Journal of Hematology, doi: 10.1002/ajh.23577.
37. Tosi, P., Zamagni, E., Cellini, C., Parente, R., Cangini, D., Tacchetti, P., Perrone, G., Ceccolini, M., Boni, P., Tura, S., Baccarani, M. & Cavo, M. (2006) First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. European Journal of Haematology, 76, 399-404.
38. Vallet, S., Mukherjee, S., Vaghela, N., Hideshima, T., Fulciniti, M., Pozzi, S., Santo, L., Cirstea, D., Patel, K., Sohani, A.R., Guimaraes, A., Xie, W., Chauhan, D., Schoonmaker, J.A., Attar, E., Churchill, M., Weller, E., Munshi, N., Seehra, J.S., Weissleder, R., Anderson, K.C., Scadden, D.T. & Raje, N. (2010) Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proceedings of the National Academy of Sciences of the United States of America, 107, 5124-5129.
39. Zhang, X., Chang, C., Zhao, Y., Wu, L., Zhang, Z. & Li, X. (2012) The effect of the combination of bisphosphonates and conventional chemotherapy on bone metabolic markers in multiple myeloma patients. Hematology, 5, 255-260.